Introduction Eradication of malaria remains one of the main aims of medicine. Despite
progress in malaria treatment, mortality rate remains high, especially in the poorest parts of …

Malaria, caused by Plasmodium species, remains a major global health concern, causing
millions of deaths annually. While the introduction of the RTS, S vaccine has shown promise …

Malaria begins when an infected mosquito injects saliva containing Plasmodium sporozoites
into the skin of a vertebrate host. To prevent malaria, vaccination is the most effective …

Extensive control efforts have significantly reduced malaria cases and deaths over the past
two decades, but in recent years, coupled with the COVID-19 pandemic, success has …

Plasmodium is an obligate intracellular parasite that requires intense lipid synthesis for
membrane biogenesis and survival. One of the principal membrane components is oleic …

Malaria transmission-blocking vaccines (TBV) are designed to inhibit the sexual stage
development of the parasite in the mosquito host and can play a significant role in achieving …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that block
Plasmodium parasite development in the mosquito midgut, thus preventing mosquitoes from …

Malaria vaccine development is hampered by extensive antigenic variation and complex life
stages of Plasmodium species. Vaccine development has focused on a small number of …

Plasmodium sporozoites invade hepatocytes, transform into liver stages, and replicate into
thousands of merozoites that infect erythrocytes and cause malaria. Proteins secreted from …

Background Malaria transmission-blocking vaccines (TBVs) aim to inhibit malaria parasite
development in mosquitoes and prevent further transmission to the human host. The …